Recombinant Low Density Lipoprotein Receptor Related Protein 1 (LRP1)

CD91; LRP; A2MR; APOER; APR; TGFBR5; Alpha-2-Macroglobulin Receptor; Prolow-density lipoprotein receptor-related protein 1; Apolipoprotein E receptor

SEQUENCE

USAGE

Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

STORAGE

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

STABILITY

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
European Journal of Vascular and Endovascular Surgery Plasma Low-density Lipoprotein Receptor-related Protein 1 Concentration is not Associated with Human Abdominal Aortic Aneurysm Presence Science: Article
Int J Cardiol Circulating soluble low-density lipoprotein receptor-related protein 1 (sLRP1) concentration is associated with hypercholesterolemia: A new potential biomarker for atherosclerosis PubMed: 26285183
International Journal of Cardiology Circulating levels of soluble low-density lipoprotein receptor-related protein 1 (sLRP1) as novel biomarker of epicardial adipose tissue pubmed:27543712
Journal of Cellular and Molecular Medicine Extracellular vesicles do not contribute to higher circulating levels of soluble LRP1 in idiopathic dilated cardiomyopathy doi:10.1111
Scientific Reports Soluble LRP1 is an independent biomarker of epicardial fat volume in patients with type 1 diabetes mellitus Pubmed:29348672
Atherosclerosis Soluble low-density lipoprotein receptor-related protein 1 as a biomarker of coronary risk: Predictive capacity and association with clinical events
Biomedical Reports Gender difference and genetic variance in lipoprotein receptor‑related protein 1 is associated with mortality
biorxiv. CMTM6 drives cisplatin resistance in OSCC by regulating AKT mediated Wnt signaling
JCI Insight CMTM6 drives cisplatin resistance by regulating Wnt signaling through ENO-1/AKT/GSK3¦Â axis 33434185